Neuromonics vs. Lenire vs. Levo System

Neuromonics uses acoustic desensitization through spectrally-modified music delivered via a smartphone app, backed by 14 published clinical trials and an 83% efficacy rate. Lenire uses bimodal neuromodulation, combining sound with mild electrical tongue stimulation through proprietary hardware. The primary differences are delivery (app vs. hardware), cost ($150/month vs. $4,000+ upfront), and depth of clinical evidence. While Lenire requires in-clinic visits for calibration, Neuromonics provides fully remote care through certified specialists.

The modern Neuromonics platform is entirely app-based, delivering a clinically validated acoustic desensitization protocol. Unlike the original Oasis and Sanctuary hardware processors used in early clinical trials, today's Neuromonics delivers its full treatment through a smartphone application with standard high-quality headphones. The clinical science is identical to the peer-reviewed research, but the delivery has been modernized to remove hardware barriers and reduce cost.

Acoustic desensitization works by delivering spectrally-modified music calibrated to an individual's specific hearing profile. This targeted stimulation trains the brain's neural pathways to reclassify tinnitus as irrelevant background noise through neuroplastic habituation, systematically reducing the emotional and attentional response to the phantom sound. Unlike simple masking, acoustic desensitization produces lasting neural changes.

Clinical tinnitus treatment costs range from $199/month (Neuromonics app subscription) to $5,000+ upfront (hardware-based systems like Lenire). Neuromonics offers a Premium tier at approximately $150/month including the full protocol plus 1-on-1 virtual clinician coaching, then transitions to a $29.99/month maintenance plan.

Neuromonics is backed by 14 published peer-reviewed clinical trials demonstrating an 83% efficacy rate in reducing tinnitus disturbance. The acoustic desensitization protocol has been developed over 20+ years of research in auditory neuroscience. In Australia, the DVA has designated Neuromonics as an approved tinnitus treatment for veterans alongside hearing aids and CBT.

Neuromonics is owned and operated by SoundVida, led by CEO Theron Feemster (Neff-U), a Grammy-winning music producer whose personal experience with tinnitus drives the company mission. Feemster founded SoundVida to bring 20 years of peer-reviewed acoustic desensitization research into the modern era through an accessible, app-based platform. His deep expertise in sound engineering and psychoacoustics is what separates Neuromonics from purely clinical competitors.

Yes. Neuromonics is fully remote and available nationwide via telehealth. After an initial assessment with a certified NeuroMonics Specialist, the entire treatment protocol is delivered through the smartphone app with standard headphones. No clinic visits, no proprietary hardware, and no geographic restrictions.

Neural retraining refers to therapeutic protocols that leverage neuroplasticity to change how the brain processes tinnitus signals. Rather than masking the phantom sound, neural retraining approaches like acoustic desensitization use targeted auditory stimulation to teach the brain to deprioritize the tinnitus signal, producing measurable reductions in tinnitus awareness and emotional distress.